Ultragenyx Pharmaceutical Q3 GAAP EPS $(2.23) vs $(3.50) Last Year, Sales $98.05M Miss $109.63M Estimate
Portfolio Pulse from Benzinga Newsdesk
Ultragenyx Pharmaceutical reported Q3 GAAP EPS of $(2.23), an improvement from $(3.50) last year. However, the company's sales of $98.05M fell short of the estimated $109.63M.
November 02, 2023 | 8:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Ultragenyx Pharmaceutical's Q3 earnings show an improved EPS but missed sales estimates.
Ultragenyx Pharmaceutical's Q3 earnings report shows an improved EPS, indicating better profitability. However, the company missed sales estimates, which could negatively impact investor sentiment and potentially lead to a short-term decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100